Arcutis Biotherapeutics, Inc.
ARQTNASDAQHealthcareBiotechnology
As of Oct 15, 2026 close
- Market cap
- $3.95B
- P/E (TTM)
- 138.67
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $19.30$31.77
- Volume (live)
- -
- Avg. volume (3M)
- 3.08M
Arcutis Biotherapeutics (ARQT) Stock Price & Financial Analysis
Arcutis Biotherapeutics Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $26.93 - $29.46 |
|---|---|
| 52-Week High | $31.77 |
| 52-Week Low | $19.30 |
| Open | $26.93 |
| Volume (last close) | 3.96M |
| Average Volume (3M) | 3.08M |
| Revenue (TTM) | 463.98M |
|---|---|
| Net Income (TTM) | 28.52M |
| Free Cash Flow (TTM) | 39.15M |
| EPS (TTM) | $0.21 |
| Profit Margin | 6.15% |
| Operating Margin | 7.38% |
| Return on Equity (ROE) | 12.93% |
| Debt to Equity | 0.49 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Payout Ratio | 0.00% |
| Market Cap | 3.95B |
|---|---|
| Shares Outstanding | 135.90M |
| P/E Ratio (TTM) | 138.67 |
| Price to Sales (P/S) | 8.52 |
| Price to Book (P/B) | 17.93 |
| EV/EBITDA | 87.42 |
| 50-Day MA | $25.39 |
|---|---|
| 200-Day MA | $25.07 |
| 1-Year Change | +39.17% |
Source: Market prices and company fundamentals. Data as of Oct 15, 2026. Data sources and methodology
Arcutis Biotherapeutics at a Glance
As of the Oct 15, 2026 close, Arcutis Biotherapeutics (ARQT) has a market capitalization of $3.95B. The stock trades at 138.7× trailing earnings and 8.5× sales. Over the trailing twelve months it earned $28.52M on revenue of $463.98M (a 6.2% profit margin) and generated $39.15M of free cash flow. Revenue grew 76.1% year over year.
As of its latest reported balance sheet, it holds $34.12M in cash and securities against $108.90M of debt, a net debt position of $74.78M.
Arcutis Biotherapeutics does not currently pay a dividend.
The share price is up 39.2% over the past year. At $29.10 (the Oct 15, 2026 close) it sits within its 52-week range of $19.30 to $31.77, above its 200-day moving average of $25.07.
Based on 9 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $37.00, 27.1% above the Oct 15, 2026 close.
Frequently Asked Questions About Arcutis Biotherapeutics
What is the current stock price for ARQT?
As of the Oct 15, 2026 close, ARQT stock trades at $29.10. The 52-week range is $19.30–$31.77, with a day range of $26.93–$29.46.
What is the P/E ratio for ARQT?
As of the Oct 15, 2026 close, Arcutis Biotherapeutics's trailing twelve-month (TTM) P/E ratio is 138.7, meaning investors pay $138.7 for every $1 of annual earnings. Arcutis Biotherapeutics operates in the Healthcare sector.
Does ARQT pay dividends?
Arcutis Biotherapeutics does not currently pay a regular dividend. The company retains its earnings to reinvest in the business. Check the Dividends tab for historical dividend information.
What do analysts recommend for ARQT?
Based on ratings from 9 professional analysts over the last 90 days, the consensus for ARQT is Buy. The average 12-month price target is $37.00, a 27.1% upside from the Oct 15, 2026 close of $29.10.
What is the market cap of ARQT?
As of the Oct 15, 2026 close, Arcutis Biotherapeutics's market capitalization is $3.95B, classifying it as a mid-cap company. Arcutis Biotherapeutics operates in the Healthcare sector within the Biotechnology industry.